Australia's most trusted
source of pharma news
Posted 17 January 2025 PM
A good start to the year for four companies which kicked off 2025 by notching either a new or expanded PBS listing and our readers wanted to know who'd made the cut, making it our top story this week.
Pfizer's PARP inhibitor Talzenna crossed the finish line alongside AstraZeneca's cancer drug Lynparza, which won an expansion. The Federal Government also announced subsidy for Servier's Risvan for schizophrenia and Sandoz' Hyrimoz - a citrate-free, high concentration biosimilar of AbbVie's Humira. Get the details in: Four PBS listings kick off 2025
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.